D'Orazio & Associates’s Cue Biopharma CUE Stock Holding History

D'Orazio & Associates’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-67	Closed	-$29K	–	238
2021 Q3	$29K	Hold	67	–	–	0.01%	297
2021 Q2	$23K	Hold	67	–	–	0.01%	242
2021 Q1	$24K	Hold	67	–	–	0.01%	220
2020 Q4	$25K	Hold	67	–	–	0.01%	202
2020 Q3	$30K	Hold	67	–	–	0.01%	167
2020 Q2	$49K	Hold	67	–	–	0.02%	141
2020 Q1	$28K	Hold	67	–	–	0.01%	161
2019 Q4	$32K	Hold	67	–	–	0.01%	180
2019 Q3	$17K	Hold	67	–	–	0.01%	216
2019 Q2	$18K	Hold	67	–	–	0.01%	203
2019 Q1	$15K	Sell	67 -66	-50%	-$12.6K	﹤0.01%	213
2018 Q4	$19K	Sell	133 -134	-50%	-$24.3K	0.01%	181
2018 Q3	$72K	Hold	267	–	–	0.03%	100
2018 Q2	$95K	Buy	+267	New	+$106K	0.04%	84

Other funds holding CUE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

D'Orazio & Associates's CUE Position: Q4 2021 in Review

D'Orazio & Associates sold out of Cue Biopharma (CUE) in Q4 2021, closing a stake of 67 shares — an estimated $29K sold.

D'Orazio & Associates first reported a position in CUE in Q2 2018 and held it in 14 quarters. The position peaked at $95K in Q2 2018. 90 funds tracked by Wall St. Rank hold CUE as of Q4 2021.

D'Orazio & Associates reported no remaining Cue Biopharma position as of Q4 2021 after selling out during the quarter.
D'Orazio & Associates sold 67 Cue Biopharma shares in Q4 2021, an estimated $29K.
D'Orazio & Associates first reported a position in Cue Biopharma in Q2 2018 and held it in 14 quarters.
D'Orazio & Associates's Cue Biopharma position peaked at $95K in Q2 2018.
90 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2021.

Based on D'Orazio & Associates's 13F filing for Q4 2021, filed 7 Feb 2022.